Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate

Ware, Joy L.; Maygarden, Susan J.; Koontz, Warren W.; Strom, Stephen C.

doi:10.1016/0046-8177(91)90159-m

Cited by 81 publications

(30 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Both Ware et al (1991) and Mellon et al (1992) used fresh material and found c-erbB-2 protein expression in 71% and in 21%, respectively, while McCann et al (1990) did not observe c-erbB-2 protein expression in formalin-fixed tissue. Ware et al (1991) also compared fresh and formalin-fixed tissue, and found that formalin fixation significantly reduced the c-erbB-2 protein immunoreactivity, which may explain the rather low c-erbB-2 protein reactivity (1.5%) in our series.…”

Section: Statisticsmentioning

confidence: 78%

“…Although c-erbB-2 protein reactivity has been noticed in many different tumours, only a few studies have been performed on prostatic cancer tissue (McCann et al, 1990;Ware et al, 1991;Mellon et al, 1992). Both Ware et al (1991) and Mellon et al (1992) used fresh material and found c-erbB-2 protein expression in 71% and in 21%, respectively, while McCann et al (1990) did not observe c-erbB-2 protein expression in formalin-fixed tissue.…”

Section: Statisticsmentioning

confidence: 99%

See 1 more Smart Citation

Prostatic carcinoma: a multivariate analysis of prognostic factors

Berner

Harvei²,

Tretli³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

Summary Tissue specimens from 150 patients with localised prostatic carcinomas and 116 patients with prostatic carcinomas with distant metastases were analysed for histological grade (WHO and Gleason) and immunoreactivity for prostate acid phosphatase (PAP), prostate-specific antigen (PSA), neurone-specific enolase (NSE), p53 protein, c-erbB-2 protein, cytokeratins (AEI/AE3) and vimentin. After stratification for the presence or absence of distant metastases, multivariate regression analysis revealed that WHO grading was the most powerful independent prognosticator, followed by age and prostate acid phosphatase expression. There was a trend towards reduced survival with decreasing prostate-specific antigen reactivity. The Gleason system showed poor prognostic ability. The analysis predicted reduced survival in the presence of extensive neurone-specific enolase reactivity, mostly because of one case of small-cell carcinoma.

show abstract

Section: Statisticsmentioning

confidence: 78%

Section: Statisticsmentioning

confidence: 99%

Prostatic carcinoma: a multivariate analysis of prognostic factors

Berner

Harvei²,

Tretli³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…36 Ware et al showed that the level of HER-2/neu expression was correlated with Gleason grade. 37 Positive immunohistochemical staining for HER-2/neu was found in 2 of 7 Gleason Grade 2-4 tumors, in 6 of 8 Gleason Grade 5-7 tumors, and in 7 of 7 Gleason Grade 8 -10 tumors. 37 Zhau et al evaluated the correlation of HER-2/neu expression and gene amplification with androgen receptor status.…”

Section: Discussionmentioning

confidence: 92%

“…37 Positive immunohistochemical staining for HER-2/neu was found in 2 of 7 Gleason Grade 2-4 tumors, in 6 of 8 Gleason Grade 5-7 tumors, and in 7 of 7 Gleason Grade 8 -10 tumors. 37 Zhau et al evaluated the correlation of HER-2/neu expression and gene amplification with androgen receptor status. 22 Western blot analysis identified HER-2/neu in 11 of 16 prostate carcinoma specimens (69%), and 12 of 15 specimens (80%) showed membranous immunostaining.…”

Section: Discussionmentioning

confidence: 92%

Evaluation of HER‐2/neu expression in prostatic adenocarcinoma

Sanchez

Sweeney

Mass³

et al. 2002

Cancer

View full text Add to dashboard Cite

BACKGROUNDSome evidence suggests a role for HER‐2/neu overexpression in prostate carcinoma progression. Reported rates of HER‐2/neu overexpression in patients with prostate carcinoma vary greatly.METHODSThe authors studied radical prostatectomy specimens from 38 patients who had biochemical failure after undergoing radical prostatectomy for prostate carcinoma. Immunohistochemistry for HER‐2/neu overexpression using the HercepTest kit (Dako Corporation, Carpenteria, CA) was employed. Two different antigen‐retrieval techniques were used: 1) the standard U.S. Food and Drug Administration (FDA)‐approved HercepTest assay and 2) a modified HercepTest, which employed an alkaline citrate buffer, pH 9.0, for antigen retrieval and a 1‐hour primary antibody incubation time. The level of HER‐2/neu expression was evaluated on a scale from 0 (no staining) to 3+ according to the published guidelines. Fluorescent in situ hybridization for gene amplification was performed on all specimens.RESULTSWith the standard technique, only one specimen had 2+ staining, and no specimens had 3+ staining. With the modified technique, 10 specimens (26%) had 2+ staining, and 9 specimens (24%) had 3+ staining. There was a significant association between the level of HER‐2/neu expression shown with the modified technique and tumor stage (P = 0.03) as well as Gleason grade (P = 0.01). None of the specimens had HER‐2/neu gene amplification.CONCLUSIONSThe authors report a simple modification of the HercepTest that resulted in an increased rate of HER‐2/neu expression, which was correlated with poor‐risk pathologic findings. The findings suggest that adenocarcinoma of the prostate should be evaluated for HER‐2/neu expression with a prostate specific immunohistochemical procedure that differs from the FDA‐approved standard procedure. Cancer 2002;95:1650–5. © 2002 American Cancer Society.DOI 10.1002/cncr.10839

show abstract

“…The expression status of ERBB2 in prostate to androgen ablation for about 24 months. The mechanism responsible for progression to hormone insensitivity cancer is unclear [10,11]. A recent study including 53 prostate cancers and nine cases of BPH suggested that is unclear and a better understanding of this problem would help to identify markers useful for predicting erbB-2 protein was overexpressed in 34% of prostate carcinomas but not in BPH tissue [12].…”

mentioning

confidence: 99%

A potential autocrine loop between heregulin‐alpha and erbB‐3 receptor in human prostatic adenocarcinoma

Leung

Weston

Gullick

et al. 1997

British Journal of Urology

View full text Add to dashboard Cite

Objective To examine the expression of heregulin-alpha stained negatively for heregulin-alpha and erbB-3. Fourteen patients had bony metastases identified by (a new member of the epidermal growth factor family) and its receptor erbB-3 in human prostate cancer by bone scintigraphy and all received androgen ablation after undergoing transurethral resection of the prosimmunohistochemistry, and to analyse their implication for clinical outcome.tate. Immunoreactivity for heregulin-alpha and erbB-3 were absent in five cases, all of whom responded to Patients and method Using specific anti-peptide antibodies, tumour samples from 50 consecutive patients hormone manipulation and remained symptom-free at the time of review (mean follow up 3 years, range with newly diagnosed prostate cancer (18 well, 15 moderately and 17 poorly differentiated) and four 2-4). Despite hormone manipulation, the nine patients overexpressing heregulin-alpha and/or erbB-3 patients with benign prostatic hyperplasia (BPH) were immunostained for heregulin-alpha (an isoform of died during a mean follow up of 2.5 years (range 0.5-4). heregulin) and erbB-3 proteins. Representative areas from each case were used to assess immunoreactivity.Conclusion The overexpression of heregulin-alpha and erbB-3 in prostate cancer is detectable by immunoResults Heregulin-alpha was expressed (i.e. Á10% of tumour cells positive) in 36 (72%) and erbB-3 in 27 staining. Activation of the type 1 growth-factor receptor system by heregulin-alpha and/or the erbB-3 (54%) of the 50 cases. High levels of expression of heregulin-alpha (>90% of tumour cells stained) receptor appears to be associated with a less favourable prognosis in advanced disease. appeared to be related to high-grade tumours, but the association did not reach statistical significance. ThereKeywords Prostate cancer, heregulin-alpha, erbB-3, autocrine loop, outcome was no correlation between the levels of expression of erbB-3 and tumour grade. All four samples from BPH cancer cells [2][3][4][5]. The expression of TGFa was upregul-

show abstract

Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate

Cited by 81 publications

References 13 publications

Prostatic carcinoma: a multivariate analysis of prognostic factors

Prostatic carcinoma: a multivariate analysis of prognostic factors

Evaluation of HER‐2/neu expression in prostatic adenocarcinoma

A potential autocrine loop between heregulin‐alpha and erbB‐3 receptor in human prostatic adenocarcinoma

Contact Info

Product

Resources

About